The global Nuclear Medicines Market witnessed significant growth in 2022, with a total market size of USD 5.2 billion. Projections indicate that this growth will continue, reaching a substantial USD 9.7 billion by the year 2032, driven by a robust compound annual growth rate (CAGR) of 6.5% over the forecast period. The primary catalyst behind this surge in market revenue is the escalating worldwide prevalence of cancer and various chronic diseases. Nuclear medicine plays a pivotal role in the diagnosis and treatment of conditions such as cancer, cardiovascular diseases, and neurological disorders. These medical procedures involve the administration of radioactive isotopes into a patient's body, utilizing the radiation they emit to produce diagnostic images or target cancerous cells for treatment.
One of the pivotal driving forces contributing to the expanding market revenue is the increasing incidence of cancer and chronic diseases across the globe. According to the World Health Organization, cancer ranks as the second leading cause of death worldwide, with an estimated 9.6 million deaths in 2018. The aging global population also contributes significantly to the growing demand for nuclear medicines. As individuals age, their susceptibility to cancer and other chronic ailments increases, resulting in a higher demand for nuclear treatments.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/6314
The diagnostic application of nuclear medicines is also a significant driver of market revenue. Nuclear medicine enables clinicians to create detailed images of a patient's body, aiding in the accurate diagnosis of medical conditions. Furthermore, these medicines are used to monitor the progression of diseases and the effectiveness of treatment regimens. The rising demand for dependable diagnostic tools and the need for monitoring medical disorders are key factors fueling the adoption of nuclear medicines for diagnostic purposes.
Key Takeaways
Product Type Outlook: The global nuclear medicines market is categorized into diagnostic nuclear medicine and therapeutic nuclear medicine based on product type. The diagnostic nuclear medicine segment is anticipated to dominate the market in terms of revenue during the forecast period. The increasing prevalence of chronic diseases such as cancer, cardiovascular ailments, and neurological disorders is driving the demand for diagnostic nuclear medicine. It is widely regarded as a crucial tool in the healthcare sector due to its ability to provide precise, non-invasive diagnoses with high sensitivity and specificity. Moreover, the expanding elderly population and growing awareness of early disease detection are expected to contribute to the revenue growth of the diagnostic nuclear medicine segment.
Conversely, the therapeutic nuclear medicine segment is forecasted to witness rapid revenue growth. The segment's growth is primarily attributed to the surging demand for effective cancer treatments, particularly targeted radionuclide therapy. Therapeutic nuclear medicine employs radioactive isotopes to treat cancer and other disorders with a high degree of precision, sparing healthy tissues from radiation damage and minimizing the adverse effects of radiation and chemotherapy. The rising incidence of cancer and the demand for personalized medicine are expected to drive the growth of the therapeutic nuclear medicine segment throughout the projected period.
Application Outlook: The global nuclear medicines market is segmented into oncology, cardiology, neurology, and other applications. Oncology is expected to account for the largest share of revenue during the forecast period. Nuclear medicine, with its use of radioactive isotopes, is instrumental in diagnosing and treating various illnesses, including cancer. Radiopharmaceuticals, containing small amounts of radioactive substances, are employed to target specific organs or tissues, enabling the detection of anomalies and the elimination of cancer cells.
The cardiology segment is poised for rapid revenue growth during the forecast period. Nuclear medicines are extensively utilized in cardiology applications for diagnosing and treating cardiovascular disorders like heart attacks and congestive heart failure. Compared to conventional diagnostic techniques, nuclear medicine offers several advantages, including enhanced accuracy and reduced patient risk.
The neurology segment is expected to hold a substantial revenue share during the forecast period. Nuclear medicines play a crucial role in diagnosing and treating a range of neurological conditions, including epilepsy, Parkinson's disease, and Alzheimer's disease. Although the use of nuclear medicines in neurology is relatively nascent, the demand for these applications is projected to surge as our understanding of brain function improves.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/6314
Regional Outlook: North America is poised to dominate the global market, contributing the largest share of revenue during the forecast period. The region's increasing incidence of cardiovascular and cancer disorders is expected to drive market growth. In the United States alone, the American Cancer Society predicts nearly 1.9 million new cancer cases in 2021. The aging population in North America is another significant driver, with the U.S. Census Bureau projecting 95 million people in this age group by 2060. Cutting-edge imaging technology adoption in healthcare institutions is also fueling market growth in the region.
The Asia Pacific market is forecasted to experience rapid revenue growth due to the growing demand for nuclear medicines in developing countries such as China and India. The region's aging population and the rising burden of chronic diseases are expected to contribute to regional market expansion. The World Health Organization estimates that by 2050, the Asia Pacific region will have more than 1.3 billion individuals aged 60 and older, accounting for over half of the global population in this age group. Additionally, increased investment in healthcare and the adoption of advanced medical technology are set to drive market growth in the region.
Europe is expected to register moderately fast revenue growth, driven by the rising incidence of chronic diseases, particularly cancer and cardiovascular conditions. Cancer is projected to be the second-highest cause of death in Europe in 2020, according to the World Health Organization. The region's well-established healthcare infrastructure and growing demand for personalized treatment are further contributing to market expansion. Additionally, the emphasis on Research and Development (RD) initiatives within the nuclear medicine sector is expected to foster market growth in Europe.
Major Companies and Competitive Landscape: The global nuclear medicines market is characterized by high competition, with several large and medium-sized players commanding a significant portion of the market revenue. Leading companies in the market employ various strategies, such as mergers and acquisitions, partnerships, product launches, and collaborations, to expand their market presence. Some of the major companies featured in the global nuclear medicines market report include:
- GE Healthcare
- Siemens Healthineers
- Curium Pharma
- Lantheus Medical Imaging
- Cardinal Health
- Jubilant Pharma
- Nordion Inc.
- Bracco Imaging S.p.A.
- Bayer AG
- Eczacıbaşı-Monrol Nuclear Products
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/6314
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
https://www.biospace.com/article/biobanks-market-trend-analysis-and-projected-growth-by-2028/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
